10 recruiting, 3 active not recruiting. 8 Phase 2, 5 Phase 1, 1 Phase 3, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Recruiting 7, Active not recruiting 1 |
| Phase 1 | 5 | Recruiting 3, Active not recruiting 2 |
| Phase 3 | 1 | Recruiting 1 |
| Phase 4 | 1 | Recruiting 1 |
Follow Daihong Liu: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Population PK-guided ATG Dosing for Haploidentical Hematopoietic Stem Cell Transplantation Anti-Thymocyte Globulin (ATG) - Hematopoietic Stem Cell Transplantation | Phase 3 | Recruiting | Daihong Liu | 324 | 2026-08-01 | 2026-10-14 |
| Individualized Application of Anti-Thymocyte Globulin(ATG)in Unrelated Donor Hematopoietic Stem Cell Transplantation Anti-Thymocyte Globulin - Hematopoietic Stem Cell Transplantation | Phase 4 | Recruiting | Daihong Liu | 324 | 2025-12-01 | 2026-06-15 |
| Study of PD-1Ab21-BCMA CAR-T Therapy for Consolidation of Multiple Myelomawith Renal Dysfunction PD-1Ab21-BCMA CAR-T cell immunotherapy - Multiple Myeloma | Phase 2 | Recruiting | Daihong Liu | 25 | 2025-09-29 | 2026-03-24 |
| Polymer-lipid Particle-delivered CAR1920 mRNA CAR-T Therapy for Relapsed/Refractory B-cell Lymphoma/Leukemia Polymer-Lipid Nanoparticle-Mediated Delivery of CD19/CD20 Dual-Targeting InViVoCAR1920 mRNA for CAR-T Cell Immunotherapy - B-cell Lymphoma Refractory | Phase 2 | Recruiting | Daihong Liu | 10 | 2025-09-01 | 2026-01-07 |
| Novel Therapies for Severe Acute GVHD (Graft-versus-host Disease) Ruxolitinib and Methylprednisolone, Methylprednisolone - GVHD, Acute, Stem Cell Transplant Complications | Phase 2 | Recruiting | Daihong Liu | 54 | 2025-06-30 | 2026-04-03 |
| Maintenance Therapy With Selinexor and Azacitidine in TP53 Mutant AML/MDS After Transplantation Maintenance Therapy with Selinexor and Azacitidine - TP53-mutated MDS and AML, Allogeneic Hematopoietic Stem Cell Transplantation | Phase 1 | Active not recruiting | Daihong Liu | 20 | 2025-06-01 | 2025-07-30 |
| Exploratory Study of EBV-TCR-T Cell Injection for EBV DNAemia After Allogeneic Hematopoietic Stem Cell Transplantation EBV-TCR-T Cell Injection - Epstein-Barr Virus Infection, Post-Transplant Lymphoproliferative Disorder | Phase 1 / Phase 2 | Recruiting | Daihong Liu | 18 | 2025-06-01 | 2026-01-28 |
| Novel First-line Therapies for Grade II Acute GVHD(Graft-versus-host Disease ) Ruxolitinib, Corticosteroids - GVHD,Acute, Stem Cell Transplant Complications | Phase 2 | Recruiting | Daihong Liu | 168 | 2025-06-01 | 2026-01-14 |
| EBV-AST Cell Injection for EBV-Associated Lymphoproliferative Disorders EBV-AST Cell Injection - Epstein-Barr Virus-Associated Lymphoproliferative Disorders, EBV-Positive Lymphoma | Phase 1 / Phase 2 | Recruiting | Daihong Liu | 18 | 2025-06-01 | 2026-03-04 |
| Enhancing CAR-T Cell Therapy Efficacy in B-cell Lymphoma Via Chidamide and PD-1 Inhibitor Combination. CAR-T Cell Therapy + Chidamide and PD-1 Inhibitor Maintenance - Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) | Phase 2 | Recruiting | Daihong Liu | 30 | 2025-05-15 | 2026-03-24 |
| Study of Targeted CD22/CD19 CAR-T Therapy for First-line Consolidation of B-cell Lymphoma CD22/CD19 CAR-T cell immunotherapy - Lymphoma | Phase 2 | Active not recruiting | Daihong Liu | 50 | 2025-04-01 | 2025-07-30 |
| EBV-AST Cell Therapy for EBV-Related Diseases After Stem Cell Transplantation EBV-AST cell - EBV-DNA Viremia | Phase 1 | Recruiting | Daihong Liu | 18 | 2025-03-26 | 2026-08-06 |
| Steroids Combined With Ruxolitinib as First-Line Therapy for Grade II Acute Graft-versus-Host Disease RUX+Steroids - Acute Graft-versus-host Disease | Phase 1 | Active not recruiting | Daihong Liu | 30 | 2025-01-17 | 2026-06-15 |
Epstein-Barr Virus Infections (1) · Graft vs Host Disease (1) · Leukemia, Myeloid, Acute (1) · Lymphoma (1) · Lymphoma, B-Cell (1) · Lymphoma, Large B-Cell, Diffuse (1) · Multiple Myeloma (1) · Recurrence (1) · Renal Insufficiency (1)
Antilymphocyte Serum (2) · Immunotherapy, Adoptive (2) · ruxolitinib (2) · Adrenal Cortex Hormones (1) · Azacitidine (1) · Maintenance (1) · Methylprednisolone (1) · N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide (1) · selinexor (1)
China (13)
Dai-Hong Liu, Dr. (3) · Dai-Hong Liu, director (1) · Dai-hong Liu, Dr. (1)